Loading…
Loading…
if you could give us any details on how you might design future studies, especially around the use of a low-dose active control
I wonder if that changes your view at all on the business, maybe some of the barriers to entry, but also the calculus on what biologics might be worth pursuing a biosimilar for?
Just curious how that program differentiates from TEPEZZA and maybe what unmet need you're looking to address in thyroid eye disease?
I actually wanted to ask about the market opportunity for TEZSPIRE and CRS nasal polyps in a mitigation that gets talked a lot about.